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Abstract
Introduction The aim of this study was to collect serial samples
of nipple aspirate (NA) and ductal lavage (DL) fluid from women
with germline BRCA1/2 mutations in order to create a
biorepository for use in identifying biomarkers of breast cancer
risk.
Methods Between March 2003 and February 2005, 52 women
with germline BRCA1 or BRCA2 mutations (median age 43
years, range 27 to 65 years) were scheduled for six-monthly NA,
DL and venesection. DL was attempted for all NA fluid-yielding
(FY) and any non-FY ducts that could be located at each visit.
Results Twenty-seven (52%) women were postmenopausal,
predominantly (19/27) from risk reducing bilateral salpingo-
oophorectomy (BSO). FY ducts were identified in 60% of all
women, 76% of premenopausal women versus 44% of
postmenopausal (P = 0.026). Eighty-five percent of women had
successful DL. Success was most likely in women with FY ducts
(FY 94% versus non-FY 71% (P = 0.049). DL samples were
more likely to be cellular if collected from FY ducts (FY 68%
versus non-FY 43%; P  = 0.037). Total cell counts were
associated with FY status (FY median cell count 30,996, range
0 to >1,000,000 versus non-FY median cell count 0, range 0 to
173,577; P = 0.002). Four women (8%) had ducts with severe
atypia with or without additional ducts with mild epithelial atypia;
seven others had ducts with mild atypia alone (11/52 (21%) in
total). Median total cell count was greater from ducts with atypia
(105,870, range 1920 to >1,000,000) than those with no atypia
(174, 0 to >1,000,000; P ≤ 0.001).
Conclusion It is feasible to collect serial NA and DL samples
from women at high genetic risk of breast cancer, and we are
creating a unique, prospective collection of ductal samples that
have the potential to be used for discovery of biomarkers of
breast cancer risk and evaluate the ongoing effects of risk
reducing BSO. DL cellular atypia was not predictive of a current
breast cancer and longer follow up is needed to determine
whether atypia is an additional marker of future breast cancer
risk in this population already at high genetic risk of breast
cancer.
Introduction
Germline BRCA1 or BRCA2 mutations are associated with a
markedly increased lifetime risk of developing breast cancer
[1,2] in female carriers. Not all mutation carriers develop
breast cancer, and the age of onset of breast cancer remains
unpredictable. Decisions regarding breast cancer risk man-
agement can therefore be problematic. Better strategies for
risk assessment, early detection and prevention of breast can-
cer are clearly a priority for research; in particular, there is a
pressing need for surrogate biomarkers that are highly specific
and sensitive indicators of breast cancer risk.
There is a well established association between atypical duc-
tal epithelium identified by histological biopsy [3], nipple
BSO = bilateral salpingo-oophorectomy; DL = ductal lavage; FNA = fine needle aspiration; FY = fluid yielding; ICMD = inadequate cellular material 
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aspiration (NA) [4] or fine needle aspiration (FNA) [5] and an
increased risk of future breast cancer. The relative risk of
developing invasive breast carcinoma for women found to
have atypical ductal hyperplasia on breast biopsy is 4.3 times
that of the general population and, when combined with a pos-
itive family history, the relative risk of invasive breast cancer
rises to 9.7 times that of the general population [3]. Women
with cellular atypia detected by cytological examination of
specimens obtained by NA or FNA have an approximately five-
fold higher relative risk of developing breast cancer than
women without cellular atypia [4,6,5], which may increase a
further six-fold when associated with a family history of breast
cancer [4]. Whether the finding of ductal epithelial atypia pro-
vides additional prognostic information for women already
identified as being at high risk of developing breast cancer by
virtue of their BRCA1/2 genetic status is not known. Although
published reports of NA and FNA have included women at
high risk of breast cancer, the proportion of these women who
carry a BRCA1/2 mutation is unknown and no conclusions
can be drawn regarding the utility of these findings specifically
in BRCA1/2 mutation carriers.
Ductal lavage (DL) can also be used to access the ductal epi-
thelium [7] and promises an improved cell yield over NAF with-
out the more invasive properties of FNA, thus providing better
opportunities to identify biomarkers of malignancy. DL also
lends itself to repeated sampling of specific ducts, which will
enable the monitoring of cytological, biological or molecular
changes over time, particularly in response to breast cancer
risk-reducing strategies such as bilateral salpingo-oophorec-
tomy (BSO) [8] and chemoprevention [9,10]. DL is unlikely to
ever sample a sufficient volume of breast to be useful as a
breast cancer detection method (screening tool) [11] but it
remains uncertain whether it can sample an adequate volume
of the intramammary ductal system to be an efficient breast
cancer risk-assessment tool [12,13]. It is important, therefore,
that prospective studies investigate whether DL is a useful
method to identify biomarkers of breast cancer risk.
Investigations into the potential role of DL as a breast cancer
risk-assessment tool have commenced. Epithelial atypia iden-
tified by DL is assigned the same clinical significance in the
Gail model of risk as atypia in histological tissue sections for
determining eligibility for the Study of Tamoxifen and
Raloxifene (STAR) trial [14]. It has been suggested that DL
can be used to identify women at "high-risk" of breast cancer
and who may benefit from tamoxifen chemoprevention [10] by
the presence of epithelial atypia [15,16]; this may also facili-
tate decision-making with regards to risk-reducing surgery.
However, there is little firm experimental evidence in support
of the routine use of DL as a risk assessment tool at the current
time and even less is known about its role in women already at
very high risk of breast cancer due to a genetic predisposition
to the disease. We initiated a prospective cohort study to col-
lect nipple aspirate fluid (NAF), DL fluid and blood samples
from women with germline BRCA1/2 mutations with the aim
of establishing a biorepository of samples to be used to iden-
tify biomarkers of breast cancer risk. Our long-term goal is to
examine these samples for ductal epithelial atypia, candidate
gene methylation frequency and candidate gene expression by
RT-PCR and DNA micro-arrays in addition to ascertaining their
proteomic profiles. This report describes our initial experience,
with the primary objective being to investigate the practicality
of establishing this collection and the nature of the DL samples
collected.
Materials and methods
Between March 2003 and February 2005, eligible women
were recruited from three familial cancer centres (Peter Mac-
Callum Cancer Centre, The Royal Melbourne Hospital, Mel-
bourne, and Westmead Hospital, Sydney, Australia), which
they had attended for the purpose of genetic testing. Women
aged between 25 and 65 years with at least one breast unaf-
fected by cancer and carrying a deleterious germline BRCA1
or BRCA2 mutation were eligible for the study. Eligible women
were invited to participate by letter following permission from
their breast specialist. Reasons for exclusion included preg-
nancy, lactation within the last 12 months, previous subareolar
or other surgery that could disrupt the ductal systems, breast
implant or breast cancer on the side of the proposed lavage.
The study was approved by each Hospital Research Ethics
Committee and all participating subjects provided written,
informed consent.
Women were scheduled to attend at six-monthly intervals for
NA and DL from each breast eligible for the study as well as
venesection (for the collection of serum and genomic DNA) for
a maximum of three years. Follow up for 10 years following
completion of the collection of DL samples with regards breast
cancer development is planned. For premenopausal women,
we would have preferred to collect samples at the same point
in each menstrual cycle but as this proved to be impracticable,
details of last menstrual period were obtained for each collec-
tion visit. All women were advised to continue with the breast
cancer surveillance programme prescribed for them by their
breast specialist prior to their participation in this study. At a
minimum, this included a recommendation to perform monthly
breast self-examination, six-monthly clinical breast examination
by their specialist and annual mammography.
Nipple aspirate fluid collection
After a clinical breast examination, NAF was collected from
each breast using the technique as previously described [17].
All NAF collected from a single breast was pooled into 0.5 ml
phosphate buffered saline and immediately placed on ice. A
0.25 ml aliquot was immediately frozen at -80°C and the
remaining 0.25 ml centrifuged to obtain a cell pellet and super-
natant, which were then also stored at -80°C for future studies.Available online http://breast-cancer-research.com/content/7/6/R1122
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Ductal lavage collection
DL was performed with the FirstCyte™ DL catheter (Cytyc
Corporation, Boxborough, MA, USA) essentially as described
[7] with minor modifications. The original DL technique
required that only NAF producing ducts were cannulated. As
our success rate at obtaining NAF was lower than anticipated,
however, we elected to attempt DL in all eligible breasts
regardless of NA success. If NAF was produced, attempts
were made to cannulate the NAF-producing duct, but if no
NAF was produced, DL was performed on ducts identified by
gentle probing of the nipple surface with a microdilator (Cytyc
Corporation). We found that the procedure was best per-
formed by two operators, one to insert the catheter and mas-
sage the breast in the optimal position and the other to operate
the inflow and outflow syringes. We defined a successful lav-
age as one in which a catheter was seated in a duct and per-
mitted free flow of saline into the duct. Cannulated ducts were
temporarily marked with a suture placed in the duct orifice and
photographed in addition to marking the location of the duct
and the radiation pattern of the instilled intraductal anaesthetic
on a nipple diagram in order to facilitate repeated cannulation
of the same duct on subsequent visits.
All women completed a 'tolerability questionnaire' immediately
after the procedure, scoring the intensity of sensation per-
ceived during the lavage procedure on a visual analogue scale
of 0 (no discomfort at all) to 10 (the worst pain imaginable) and
comparing the intensity of sensation to that experienced dur-
ing mammography.
Ductal lavage preparation
Between 10 and 12 ml of DL fluid was recovered from each
duct; initially 2 ml was separated into 30 ml Cytolyt™ solution
(Cytyc Corporation) for transport to the laboratory for cytolog-
ical processing and the remainder placed on ice. A significant
proportion of our initial samples were considered to have inad-
equate cellular material for cytological diagnosis (ICMD). Con-
sequently, from September 2003, half the recovered DL fluid
was used for cytological analysis. The remaining lavage fluid
was temporarily placed on ice and processed within 2 h into
cell pellets of approximately 10,000 cells/pellet and superna-
tants stored separately at -80°C. Total cell counts were
obtained using a haemocytometer and Trypan Blue at the start
of the handling process.
Cytological examination
DL samples were processed for cytological examination using
the ThinPrep® technique [18], stained by the Papanicolaou
method and scored for the proportion of epithelial cells, cyto-
logical appearance and epithelial cell atypia by one of us (WM)
using the scoring system described in the multi-centre DL
study [7]. Briefly, there were five diagnostic categories: inade-
quate cellular material for diagnosis (ICMD; samples with <10
epithelial cells per slide), benign, mild atypia, severe atypia and
malignant. All women were informed of the cytological score.
If severe cytological atypia or malignant cells were identified,
the woman was referred back to her specialist for repeat clin-
ical breast examination and mammography if this had not been
performed in the preceding six months, and breast ultrasound
and biopsy of any suspicious lesion. Breast MRI was not per-
formed routinely. Suspicious lesions were managed at the dis-
cretion of the treating specialist; when no lesion was identified,
the woman was reviewed at three-monthly rather than six-
monthly intervals with additional screening investigations per-
formed at the specialist's discretion.
Data collection and statistical analysis
All data were recorded on study specific case record forms
and entered into a database created using Microsoft Access
software (Microsoft Corp. Redmond, WA, USA). Data consist-
ency checks were made at the time of data entry and subse-
quently at the time of statistical analysis. All BRCA1/2
mutation carriers registered on the study prior to February
2005 were included in the analysis. Baseline characteristics of
these women were summarised in addition to the characteris-
tics of their breasts and cannulated ducts.
Fisher's exact test was used to compare the proportion of
NAF-producing breasts, successful cannulations and ICMD
ducts, according to both menopausal status and previous his-
tory of breast cancer, parity and breast feeding. The nonpara-
metric Mann-Whitney test was used to compare total cell
counts (expressed as both cells/ml and total cells) according
Table 1
Characteristics of all study participants
Characteristic N %
Total 52
Age (years; median, range) 43 (27–65)
BRCA mutation
A1 25 48
A2 27 52
Menopause status
Premenopausal 25 48
Postmenopausal 27 52
BSO <50 years 19 37
Current use (study entry)
OCP 3 6
HRT 3 6
Tamoxifen 4 8
Previous diagnosis of breast cancer 21 40
Parous 44 85
Breast fed 38 73
BSO, bilateral salpingo-oophorectomy; HRT, hormone replacement 
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to menopausal status, NAF-producing status, previous history
of breast cancer, parity and breast feeding, development of
breast cancer during the study and the presence of DL cyto-
logic atypia. No adjustments have been made for multiple com-
parisons and all P values are two-sided. Statistical analysis
was performed using StatXact version 6.0 (Cytel Software
Corporation, Cambridge, MA, USA).
Results
We recruited 52 women with BRCA1/2 mutations (Table 1)
with a median age of 43 years (range 27 to 65 years). Twenty-
seven women (52%) were postmenopausal, many (n = 19) as
a consequence of a risk-reducing BSO. Median age at meno-
pause was 45 years (range 30 to 54 years). Twenty-one
(40%) had a prior diagnosis of unilateral breast cancer. All but
two had received adjuvant chemotherapy and only four
Table 2
Summary of nipple aspiration and ductal lavage episodes
Women Eligible breasts
N% P N% P
Eligible for study 52 83
Premenopausal 25 48 43 52
Postmenopausal 27 52 40 48
Previous BC 21 40 21 25
No previous BC 31 60 62 75
Parous 44 85 68 82
Non-parous 8 15 15 18
Breast fed 38 74 60 72
No breast feeding 14 27 23 28
FY 31 60 45 54
Premenopausal 19 76 30 70
Postmenopausal 12 44 0.026 15 38 0.004
Previous BC 11 52 11 52
No previous BC 20 65 0.405 34 55 1.000
Parous 25 57 34 50
Non-parous 6 75 0.450 11 73 0.152
Breast fed 21 55 28 47
No breast feeding 10 71 0.353 17 74 0.030
No. DL visits (median (range)) 2 (1–5)
Successful DL cannulation 44 85 64 77
FY 29 94 40 89
Non-FY 15 71 0.049 24 63 0.008
Premenopausal 22 88 33 77
Postmenopausal 22 81 0.705 31 78 1.000
Previous BC 17 81 17 81
No previous BC 27 87 0.700 47 76 0.769
Parous 36 82 53 78
Non-parous 8 100 0.330 11 73 0.738
Breast fed 32 84 47 78
No breast feeding 12 86 1.000 17 74 0.772
P is for Fisher's exact test. BC, breast cancer; FY, breasts producing nipple aspirate fluid; DL, ductal lavage.Available online http://breast-cancer-research.com/content/7/6/R1122
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received adjuvant therapy with tamoxifen. None of the 31 unaf-
fected women were taking tamoxifen for breast cancer preven-
tion. Consequently, we were unable to investigate separately
the effects of different cancer treatments from the previous
diagnosis of breast cancer per se on NA and DL. Eighty-five
percent were parous and seventy-three percent had breast-
fed their children.
NA and DL were attempted in all women on at least one occa-
sion; median two visits, range 1 to 5 visits (Table 2). Success
of NA was related to menopause status (70% of breasts from
premenopausal women had fluid-yielding (FY) ducts versus
38% of breasts from postmenopausal women, P = 0.004) but
not related to a previous history of contralateral breast cancer
(Table 2). Forty-four women (85%) had a successful DL
attempt on at least one occasion. Successful ductal cannula-
tion was related to FY status (P = 0.008) but not related to
menopausal status, previous history of contralateral breast
cancer or lactation or parity (Table 2). Current exogenous hor-
mone use had no significant effect on FY status (data not
shown), but very few patients were current hormone users.
The ability to re-cannulate the same duct on subsequent occa-
sions was determined (Fig. 1). We found that it was more dif-
ficult to repeatedly re-cannulate the same duct than we had
anticipated, partly due to the close anatomical location of
some ducts. For women who attended for more than one lav-
age appointment, 37%, 39%, 13% and 50% of previously
cannulated ducts could not be re-cannulated at each subse-
quent visit, respectively. By contrast, a proportion of ducts lav-
aged at each visit were new ducts never previously
cannulated, 40%, 33%, 9% and 21% of ducts cannulated on
the second, third, fourth and fifth visits, respectively.
Tolerability
The DL procedure was well tolerated with a median visual ana-
logue scale reading of 2.8/10 (range 0 to 8/10). Three women
(6%) had not yet commenced mammographic screening. Of
the remainder, 33% of the women thought that the procedure
was comparable to the discomfort experienced by mammog-
raphy, while 33% reported that the procedure caused more
discomfort and 29% less discomfort than mammography.
Cytological analysis
DL samples were more likely to have adequate cellular material
for diagnosis if they were collected from FY ducts (P = 0.037;
Table 3). Allocating 50% of the DL sample for cytological anal-
ysis did not reduce the proportion of ICMD samples (data not
shown). Similarly, the total cell counts were associated with
FY status only (P = 0.002). So far, we have found no statistical
difference in total counts between the small number (n = 5) of
women who developed breast cancer during the study versus
women who did not.
Examples of cytological scoring categories are illustrated in
Fig. 2. Four women (8%) had severe atypia diagnosed in at
least one DL sample, and three of these had mild atypia noted
in at least one of their other DL samples. Seven additional
women (13%) also had mild atypia alone in at least one DL
sample. Overall, there were 20 ducts with atypia from 11
women; 4 of these were classed as severe atypia and 16 as
mild atypia. None of the ducts (0/4) with severe atypia were
non-FY and two of the ducts with mild atypia were non-FY (2/
16). Two of eleven (18%) women with atypia had a previous
diagnosis of breast cancer. DL samples with any atypia were
significantly more cellular than samples without atypia (P <
0.001; Table 3). All of the women with severe atypia had a full
clinical assessment by a breast surgeon, including an addi-
tional mammogram and breast ultrasound. Three of them also
had a breast MRI. No suspicious lesions were identified, but
Figure 1
The frequency of individual ducts lavaged on repeat visits per woman The frequency of individual ducts lavaged on repeat visits per woman. The 'Total number of ducts' equals all ducts ever accessed on at least one 
previous occasion. 'Repeated ducts' equals ducts re-accessed on that specific visit. 'New ducts' equals a new duct not accessed on a previous visit.Breast Cancer Research    Vol 7 No 6    Mitchell et al.
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one of them had two fibroadenomas diagnosed by imaging
and confirmed by biopsy in the breast with atypia.
Five women, all with BRCA1 mutations, were diagnosed with
breast cancer (median five months following study entry); the
features of their cancers and associated DL samples are
summarised in Table 4. Only one cancer was detected
through a scheduled annual screening mammogram, and was
clinically impalpable at the time of diagnosis. All four other can-
cers were interval cancers discovered by self-detection of a
new breast lump. All prior screening mammograms and clinical
breast examinations were reported as normal. One woman
had mild cytological atypia in the DL sample from the cancer-
containing breast but no cytological atypia was identified in
the DLs from the cancer-containing breast of the other three
women successfully lavaged. Thus, there appeared to be no
correlation between the presence of cytological atypia and the
short term development of cancer.
Discussion
This is the first published study, to our knowledge, to describe
the findings from serial NA and DL in a cohort of women with
germline mutations in BRCA1 and BRCA2 genes. We have
demonstrated that it is both acceptable and feasible to collect
these samples and we have established a prospective collec-
tion of samples with ongoing epidemiological data that will be
available for future breast cancer biomarker discovery.
Table 3
Summary of associations between patient characteristics and ductal lavage cellularity
ICMD ducts Cell count/ml Total cell count/specimen
% P1 Median Range P2 Median Range P2
Overall 39 600 0 to 909,090 9481 0 to 21,818,160
FY Status
FY duct 32 1625 0 to 909,090 30,996 0 to 21,818,160
Non-FY duct 57 0.037 0 0 to 4959 <0.001 0 0 to 173,577 0.002
Menopausal status
Premenopausal 28 1000 0 to 50,000 22,000 0 to 600,000
Postmenopausal 51 0.034 0 0 to 909,090 0.044 0 0 to 21,818,160 0.055
Previous diagnosis of BC
Previous BC 31 1000 0 to 909,090 22,000 0 to 21,818,160
No BC 43 0.361 390 0 to 50,000 0.191 6000 0 to 1,229,667 0.189
Parity
Parous 35 750 0 to 909,090 12,000 0 to 21,818,160
Non-parous 58 0.073 0 0 – 50,000 0.395 0 0 to 600,000 0.261
Breast feeding
Breast fed 31 1000 0 to 909,090 15,426 0 to 21,818,160
No breast feeding 57 0.024 0 0 to 50,000 0.091 0 0 to 600,000 0.057
BC during study
BC 20 6666 0 to 25,850 79,992 0 to 542,850
No BC 40 0.645 500 0 to 909,090 0.133 7688 0 to 21,818,160 0.261
Cytologic atypia
Mild atypia 5355 84 to 50,000 105,870 1920 to 1,229,667
Severe atypia 3591 1917 to 18,666 0.75 113,752 48,000 to 447,996 0.892
Atypia (mild + severe) 0 4875 84 to 50,000 105,870 1920 to 1,229,667
No atypia 50 <0.001 14 0 to 909,090 <0.001 174 0 to 21,818,160 <0.001
Cellularity is expressed both as cells/ml, to account for variations in the volume of DL collected, as well as total number of cells/specimen in order 
to permit comparisons between our results and other published studies. P1 = Fisher's exact test; P2 = Mann-Whitney test. BC, breast cancer; 
ICMD, inadequate cellular material for diagnosis; FY, ducts producing nipple aspirate fluid.Available online http://breast-cancer-research.com/content/7/6/R1122
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We found that we could obtain ductal fluid by NA in 60% of
our cohort overall, but that NAF was more often obtained from
premenopausal women. Our overall figures are less success-
ful than reported by most (48% to 99%) [19-21,7,22,23]. One
explanation is that we had a high proportion of postmenopau-
sal women in our cohort (52%) and the proportion of premen-
opausal women with FY ducts in our cohort is significantly
higher than the proportion of postmenopausal women with
them. Additional explanations could include the persistence
with which the collection of NAF was pursued. For studies of
NAF only, it is appropriate to be particularly persistent but in
our study, as this was the preliminary to subsequent lavage
attempts, we had concerns regarding engorgement of the nip-
ple as a consequence of vigorous attempts to elicit NAF and
time constraints were also important. It is possible that if we
had been more persistent our overall NAF success rates may
have improved a little, although we consider it unlikely that this
would have changed our results substantially.
Half of the women in our cohort were postmenopausal despite
the median age of only 43 years, predominantly because of
risk-reducing BSO (19/27 postmenopausal women). Seventy-
six percent of the premenopausal women had FY ducts in
contrast to forty-four percent of postmenopausal women. Sim-
ilar low rates of FY ducts in ovariectomised women have been
observed previously; BL King, Yale, found FY ducts in only
23% of women with oophorectomy with or without selective
estrogen receptor modulator (SERM) use (personal communi-
cation). Conversely, Kurian et al. [23] found no effect of men-
opausal status on the ability to elicit NAF; however, they had a
lower overall NAF success rate (48% compared to 60% in our
study), which may account for this apparent discrepancy in
results. During the course of our study, more women are
planning to have a risk-reducing BSO and we will be able to
investigate the temporal relationship between NAF produc-
tion/DL cellularity and BSO.
The ability to re-cannulate the same duct on repeated occa-
sions was less successful than we had anticipated (Fig. 1).
Frequently, it was simply that we were unable to locate the
duct orifice or, to a lesser extent, the duct was perforated dur-
ing the cannulation attempt. On most occasions, we could be
sure that the same and/or different ducts were cannulated as
a consequence of the combined information from the photo-
graphs, nipple diagrams and anaesthetic radiation pattern.
Despite this information, however, it is possible that we may
have re-cannulated the same duct but scored it at a different,
although close, location or conversely, that we have recorded
a successful re-cannulation but in fact cannulated a different
duct due to the close proximity of two duct orifices.
If the DL sample had adequate material for cytological diagno-
sis (non-ICMD samples), the cellularity was comparable to
previous reports [7]. In contrast to previous reports, however,
we found that a higher proportion of our samples were catego-
Figure 2
Examples of ductal epithelial cells collected by ductal lavage Examples of ductal epithelial cells collected by ductal lavage. (a) 
Benign ductal epithelial cells. (b) Epithelial cells with mild atypia. (c) 
Epithelial cells with severe atypia.Breast Cancer Research    Vol 7 No 6    Mitchell et al.
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rised as ICMD (39% in contrast to 22% [7]). The higher pro-
portion of ducts with ICMD may be due to a variety of factors.
We consider menopausal status to be the most important fac-
tor associated with cellularity, but the practice of allocating
only a small proportion (initially 20% then later 50%) of the
sample, in contrast to previous reports in which the entire lav-
age sample was used for cytological analysis, may also have
contributed to the higher ICMD rate. We found that DL cellu-
larity was related to both FY and menopausal status, which is
consistent with the close relationship between these two fac-
tors. We are not able to comment on the effect of prior expo-
sure to chemotherapy or tamoxifen or current exogenous
hormone use as separate categories on cannulation success
rates or sample cellularity as almost all women previously
affected by breast cancer had received chemotherapy and few
received tamoxifen.
Four women (8%) were identified with severe cytological aty-
pia (in at least one duct on at least one occasion) and 7/52
(13%) with mild cytological atypia, which is consistent with the
results from the multicentre DL study (6% and 17% of women
had severe or mild atypia, respectively [7]) and from DL
studies of other high-risk women in which 23% (7/30) [24]
and 28% (17/75) [23] had any atypia (severe or mild). We
might have expected to see a higher rate of atypia in our study
if the hypothesis that atypia is related to future breast cancer
risk is correct, as the women in our study should be at very
high risk due to their genetic status. However, the large num-
bers of women who have undergone risk-reducing BSO in our
study may have reduced the overall breast cancer risk in our
cohort. The majority of samples with atypia in our study (90%)
were from FY ducts, in contrast to 29% reported by Kurian et
al. [23]. It is difficult to postulate a biological explanation for
Table 4
Demographic, tumour and ductal lavage characteristics of women who developed breast cancer after study entry
Subject
PMC13 PMC11 PMC14 PMC15 RMH08
Age (years) 53 51 41 48 37
BRCA mutation A1 A1 A1 A1 A1
Menopause status Post Post Pre Post Pre
Prior contralateral breast cancer (age in years) No Yes (42) Yes (35) Yes (38) Yes (34)
Previous mammogram (months) 12 (normal) 7 (normal) 5 (normal) 5 (normal) 7 (normal)
Previous CBE (months) 6 1 5 5 7
'Regular' BSEa Yes Yes Yes Yes Yes
Mode of detection Mammography Self Self Self Self
Distance from nipple (cm) 5 3 Not recorded Not recorded 2
Histological characteristics Atypical medullary Lobular Ductal Ductal Ductal
Size (mm) 5.2 20 10, 14, 10 
(X3 separate foci)
1.8 5
Grade 3 3 3 3 3
ER status Negative Negative Negative Negative Negative
PR status Negative Negative Negative Negative Negative
Nodes Negative Negative Negative Negative Negative
Ductal lavage
Previous (months) 5 1 5 12 4
No. ducts cannulated/breast 1 (X1occ) 2 (X1occ) 1 (X2occ) 1 (X1occ) Unsuccessful
Cell count (duct)/ml 6,666 2,500, 6,666 47,700 + 4,000 15,000
Total cell count (duct) 79,992 35,000, 93,324 525,555 + 40,000 180,000
Cytology score Mild atypia Benign Benign No epithelial cells
a'Regular' as reported by subject (frequency not recorded). BSE, breast self examination; CBE, clinical breast examination; ER, oestrogen 
receptor; PR, progesterone receptor.Available online http://breast-cancer-research.com/content/7/6/R1122
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this discrepancy but it is possible that it is due to a combina-
tion of the small numbers of samples with atypia in each study,
in addition to the known difficulties in cytological interpreta-
tion. All the atypical samples in the Kurian et al. study were
scored as mildly, rather than severely, atypical, as were most
of ours, and it is the differentiation between benign and mildly
atypical that is the most debated in cytological scoring.
Five women were diagnosed with breast cancer during our
study; one had only mild cytological atypia while the others
had no atypia in their DL samples. These women are likely to
have had an established malignancy at study entry, although
this was not detected by pre-study assessment. Our results
are consistent with previous reports that have suggested that
both NAF and DL fluid have low sensitivity for the identification
of an established malignancy. For NAF, only a low percentage
of specimens contain severely atypical or malignant cells, even
when the aspirate is obtained from a known cancer-bearing
breast (sensitivity 4% [22] to 21% [22,19]). Two studies have
reported on the low sensitivity (41% [25], 11% (Wiley, K.: His-
tology of intraductal lesions – correlation and sampling issues.
Lynn Sage Breast Cancer Symposium, Chicago 2003,) [26])
of DL for established breast cancer. The reasons for such low
sensitivity are uncertain, but are possibly related to sampling
error by the cannulation of only a limited number of ducts per
breast and the blockage/disruption of the ductal system by
non-invasive or invasive tumours.
We believe that it is important to be aware of the poor corre-
lation between DL atypia and current breast cancer and that
the significance of detecting DL atypia in a high-risk woman is
unknown. The finding of no atypia should not reassure a high-
risk woman that no malignancy is present and she should be
encouraged to continue with regular breast self examination,
clinical breast examination and mammography. The finding of
atypia requires investigation to exclude malignancy, but we do
not consider that there is sufficient evidence currently to con-
sider DL atypia as an additional risk factor in support of pro-
phylactic mastectomy in an otherwise high-risk population.
Conclusion
Our results demonstrate that DL is an acceptable, minimally
invasive method of repeatedly accessing the breast ductal
environment, although it requires further validation before it
can be established as a breast cancer risk assessment tool,
particularly in the high-risk population. It does not appear to be
a sensitive breast cancer screening method. We are creating
a prospective repository of biologic samples that have the
potential to be used to identify biomarkers of breast cancer
risk in a high-risk population. Two further cohorts of 50
BRCA1/2 mutation carriers each in the UK and US are being
recruited using a similar protocol, which will permit a com-
bined analysis of results in the future. In the first two years of
our study, five women have developed breast cancer, consist-
ent with published rates of breast cancers in this high-risk
group [1,2,27]. If similar rates of breast cancer development
are observed in the UK and US centres, it is probable that
these samples can be used to identify cytological, biological
and molecular biomarkers for breast cancer risk in women with
germline BRCA1/2 mutations.
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